TCT-599 Final procedural, 30-day and 6-month angiographic, clinical and OCT outcomes from the DIRECT II Trial using the Svelte Integrated Delivery System with Enzymatic Bioabsorbable Sirolimus Coating

Background The Svelte (New Providence, NJ) sirolimus-eluting coronary stent utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon control bands (BCBs) affixed to a 0.014 integrated wire...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2014-09, Vol.64 (11), p.B175-B175
Main Authors: Verheye, Stefan, Carrié, Didier, Khattab, Ahmed, Slagboom, Ton, berland, jacques, Horak, Jan, Vrolix, Mathias, Smits, Pieter C, Legrand, Victor M, Van Mieghem, Nicolas M, Fajadet, Jean, Schofer, Joachim, Stella, Pieter R
Format: Article
Language:English
Subjects:
Cardiology
Cardiovascular
Cost control
Internal Medicine
Stents
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The Svelte (New Providence, NJ) sirolimus-eluting coronary stent utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon control bands (BCBs) affixed to a 0.014 integrated wire with shapeable tip.
ISSN:0735-1097
1558-3597
DOI:10.1016/j.jacc.2014.07.664